Clinical Trial

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients

Study acronym: SWISS OPTICOV
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 18, 2026 (before its estimated April 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy direct antiviral agents (remdesivir + nirmatrelvir/r) versus the reference monotherapy (nirmatrelvir/r alone) and to assess the efficacy and safety of increasing the nirmatrelvir/r course from 5- to 10 days in immunocompromised patients diagnosed with asymptomatic or mild to moderate Coronavirus Disease 2019 (COVID-19).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-05.
Trial Details
NCT Number NCT07406217
Lead Sponsor Calmy Alexandra
Collaborators: ANRS, Emerging Infectious Diseases
Conditions COVID-19, Immunodeficiency
Enrollment 256 participants
Start Date 2023-04-27
Primary Completion 2026-04-10 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-18